Wanbury Ltd
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Wanbury Ltd is navigating a pivotal transition from a turnaround phase to a growth trajectory, as highlighted by management's focus on operational efficiency and regulatory compliance. The company's strategic shift towards specialty and chronic-therapy products, alongside the successful clearance of international regulatory inspections, positions it favorably in the competitive landscape. However, while revenue growth is expected to remain stable, margins are under pressure due to external factors such as geopolitical tensions and raw material cost volatility. Vista's financial outlook reflects these dynamics, projecting continued revenue growth but acknowledging margin challenges, leading to a cautious investment stance. The anticipated upside is constrained by the current valuation, which suggests a potential value trap. Over the next 12-24 months, Wanbury's key opportunities lie in its robust pipeline of new molecule launches and improved operational efficiencies, while watchpoints include geopolitical risks and the need for sustained regulatory compliance
Why We Like This Stock
- Successful completion of a three-year operational turnaround, enhancing financial stability and plant utilization
- Strategic pivot towards high-margin specialty and chronic-therapy products, supported by a robust pipeline of new molecule launches
- Improved regulatory compliance and operational efficiency through digital transformation initiatives
Things To Watch Out For
- Ongoing margin pressure due to geopolitical tensions and potential volatility in raw material costs
- Dependence on the API business, which may be vulnerable to export-market fluctuations
- Cautious investor sentiment reflected in the current valuation, indicating a potential value trap
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 578 | 600 | 650 | 667 | 732 |
| Profit Before Tax (Cr.) | 31 | 28 | 64 | 54 | 62 |
| PBT Margin | 5.3% | 4.7% | 9.8% | 8.0% | 8.5% |
| Net Profit (Cr.) | 30 | 22 | 63 | 40 | 46 |
| Earnings Per Share | 8.7 | 6.4 | 18.1 | 11.5 | 13.3 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API portfolio includes Metformin Hcl, Sertraline Hcl, Tramadol Hcl, Mefenamic Acid , Metformin Hcl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine Hcl, and Anaesthetic API. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was founded in 1988 and is headquartered in Navi Mumbai, India.